EUVIMEDEUVIMED entdecken
Open Access

Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation

Michael L Cheng iD, Yeying Huang, Nhi Luong, Jaclyn LoPiccolo, Mizuki Nishino iD, Lynette M Sholl iD, Lucian R Chirieac iD, Alison D Santucci iD, Michael S Rabin, Pasi A Jänne iD, Shodeinde Coker iD, Jennifer R Diamond iD und 3 weitere

JCO Precision Oncology · 2023-06 · (7)

DOI: 10.1200/po.22.00633 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2023-06. Verfasst von Michael L Cheng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Nuclear Proteins, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nuclear ProteinsAntineoplastic AgentsHumansTranscription FactorsCell Cycle ProteinsBromodomain Containing Proteins

Substanzen

Nuclear ProteinsTranscription FactorsAntineoplastic AgentsCell Cycle ProteinsBRD4 protein, humanBromodomain Containing Proteins

Autor:innen und Institutionen

  • Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Boston Medical Center, Boston, MA.

ORCID-Profile: Michael L Cheng, Mizuki Nishino, Lynette M Sholl, Lucian R Chirieac, Alison D Santucci, Pasi A Jänne, Shodeinde Coker, Jennifer R Diamond, John Hilton, Geoffrey I Shapiro

Förderung

  • NCI NIH HHS

Zitieren

APA

Cheng, M. L., Huang, Y., Luong, N., LoPiccolo, J., Nishino, M., Sholl, L. M., Chirieac, L. R., Santucci, A. D., Rabin, M. S., Jänne, P. A., Coker, S., Diamond, J. R., Hilton, J., Shapiro, G. I., & French, C. A. (2023). Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation. JCO Precision Oncology. https://doi.org/10.1200/po.22.00633

Vancouver

Cheng ML, Huang Y, Luong N, LoPiccolo J, Nishino M, Sholl LM, et al. Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation. JCO Precision Oncology. 2023. doi:10.1200/po.22.00633

BibTeX
@article{Cheng2023,
  author = {Cheng, Michael L and Huang, Yeying and Luong, Nhi and LoPiccolo, Jaclyn and Nishino, Mizuki and Sholl, Lynette M and Chirieac, Lucian R and Santucci, Alison D and Rabin, Michael S and Jänne, Pasi A and Coker, Shodeinde and Diamond, Jennifer R and Hilton, John and Shapiro, Geoffrey I and French, Christopher A},
  title = {Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation},
  journal = {JCO Precision Oncology},
  year = {2023},
  number = {7},
  doi = {10.1200/po.22.00633}
}
Kostenlos starten →